Ipsen starts resupply of Increlex


Ipsen's (IPSEY -1%) U.S. affiliate Ipsen Biopharmaceuticals says one batch of its orphan drug Increlex (mecasermin [rDNA origin] injection) will be available in the U.S. on June 2. Additional lots will be available over the coming months.

Increlex is used to treat children afflicted with a form of growth failure known as severe primary IGF-1 deficiency which can cause permanent short stature.

The supply interruption began almost a year ago due to manufacturing problems at Lonza Biologics, the maker of Increlex's active ingredient.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs